Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.74 EUR | +2.49% | +4.75% | -6.36% |
04-26 | ResMed tops quarterly profit estimates on strong demand for sleep apnea devices | RE |
04-23 | PHILIPS NV : Jefferies reiterates its Sell rating | ZD |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- This company will be of major interest to investors in search of a high dividend stock.
Weaknesses
- With a 2024 P/E ratio at 27.86 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.36% | 19.11B | B | ||
+8.07% | 219B | B | ||
+6.59% | 183B | B- | ||
+11.26% | 133B | B- | ||
+26.57% | 108B | A- | ||
+0.65% | 63.06B | A- | ||
+13.35% | 52.02B | B+ | ||
-0.62% | 48.2B | B+ | ||
-0.93% | 40.37B | A | ||
+11.54% | 39.35B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PHIA Stock
- Ratings Philips NV